After review by the Data and Safety Monitoring Board, the dosing of OCU200 in patients with diabetic macular edema (DME) will continue.

The therapeutic landscape for diabetic macular edema (DME) is rapidly evolving with the introduction of novel treatments, protocols, and delivery methods designed to improve visual outcomes and ...

Are you ignoring the early signs of kidney disease in diabetes? As diabetic kidney disease is on the rise, here’s what ...

Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...

This week Bobbi Conner talks with Dr. Peter Tang about potential diabetes related vision changes. Dr. Tang is an ...

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic ...

This article will explain why eye screenings are crucial, how diabetic retinopathy develops, and what you can do to protect ...

Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal ...

ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) ...

Ocugen (OCGN) announced that the Data and Safety Monitoring Board for the OCU200 clinical trial recently convened and reviewed safety data ...